These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 39116700)

  • 1. A novel approach for health state valuation: Multiple bounded dichotomous choice compared to the traditional standard gamble.
    Poder TG; Ameri H
    Soc Sci Med; 2024 Sep; 357():117173. PubMed ID: 39116700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four approaches in eliciting health state utilities with SF-6Dv2.
    Ameri H; Poder TG
    Eur J Health Econ; 2024 Sep; ():. PubMed ID: 39340750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension.
    Wu J; Xie S; He X; Chen G; Bai G; Feng D; Hu M; Jiang J; Wang X; Wu H; Wu Q; Brazier JE
    Pharmacoeconomics; 2021 May; 39(5):521-535. PubMed ID: 33598860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valuing the SF-6Dv2 in the capital of Iran using a discrete choice experiment with duration.
    Daroudi R; Zeraati H; Poder TG; Norman R; Olyaeemanesh A; Sari AA; Ameri H
    Qual Life Res; 2024 Jul; 33(7):1853-1863. PubMed ID: 38630166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Web Comparison of Three Contingent Valuation Techniques in Women of Childbearing Age: The Case of Ovulation Induction in Quebec.
    Dieng A; He J; Poder TG
    Interact J Med Res; 2020 Feb; 9(1):e13355. PubMed ID: 32027310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining the Feasibility and Acceptability of Valuing the Arabic Version of SF-6D in a Lebanese Population.
    Kharroubi SA; Beyh Y; Harake MDE; Dawoud D; Rowen D; Brazier J
    Int J Environ Res Public Health; 2020 Feb; 17(3):. PubMed ID: 32041284
    [No Abstract]   [Full Text] [Related]  

  • 8. Do Discrete Choice Experiments Approaches Perform Better Than Time Trade-Off in Eliciting Health State Utilities? Evidence From SF-6Dv2 in China.
    Xie S; Wu J; He X; Chen G; Brazier JE
    Value Health; 2020 Oct; 23(10):1391-1399. PubMed ID: 33032784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creating an SF-6Dv2 social value set for New Zealand.
    Sullivan T; McCarty G; Ombler F; Turner R; Mulhern B; Hansen P
    Soc Sci Med; 2024 Aug; 354():117073. PubMed ID: 38959817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valuation of the SF-6D Health States Is Feasible, Acceptable, Reliable, and Valid in a Chinese Population.
    Lam CL; Brazier J; McGhee SM
    Value Health; 2008; 11(2):295-303. PubMed ID: 18380642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuing the SF-6Dv2 Classification System in the United Kingdom Using a Discrete-choice Experiment With Duration.
    Mulhern BJ; Bansback N; Norman R; Brazier J;
    Med Care; 2020 Jun; 58(6):566-573. PubMed ID: 32221100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valuing SF-6Dv2 in Australia Using an International Protocol.
    Mulhern B; Norman R; Brazier J
    Pharmacoeconomics; 2021 Oct; 39(10):1151-1162. PubMed ID: 34250578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?
    Mulhern B; Norman R; Shah K; Bansback N; Longworth L; Viney R
    Med Decis Making; 2018 Apr; 38(3):306-318. PubMed ID: 29084472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility, comparability, and reliability of the standard gamble compared with the rating scale and time trade-off techniques in Korean population.
    Kim SH; Lee SI; Jo MW
    Qual Life Res; 2017 Dec; 26(12):3387-3397. PubMed ID: 28801862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consistency Between Three Different Ways of Administering the Short Form 6 Dimension Version 2.
    Poder TG; Fauteux V; He J; Brazier JE
    Value Health; 2019 Jul; 22(7):837-842. PubMed ID: 31277832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
    Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
    Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A framework for estimating health state utility values within a discrete choice experiment: modeling risky choices.
    Robinson A; Spencer A; Moffatt P
    Med Decis Making; 2015 Apr; 35(3):341-50. PubMed ID: 25349189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity, feasibility and acceptability of time trade-off and standard gamble assessments in health valuation studies: a study in a multiethnic Asian population in Singapore.
    Wee HL; Li SC; Xie F; Zhang XH; Luo N; Feeny D; Cheung YB; Machin D; Fong KY; Thumboo J
    Value Health; 2008 Mar; 11 Suppl 1():S3-10. PubMed ID: 18387064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the monetary value of a Quality-Adjusted Life-Year in Quebec.
    Kouakou CRC; He J; Poder TG
    Eur J Health Econ; 2024 Jul; 25(5):787-811. PubMed ID: 37656261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of a valuation function for a diabetes mellitus-specific preference-based measure of health: the Diabetes Utility Index.
    Sundaram M; Smith MJ; Revicki DA; Miller LA; Madhavan S; Hobbs G
    Pharmacoeconomics; 2010; 28(3):201-16. PubMed ID: 20151725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.